42 terminated. 42 Phase 2, 6 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 42 | Terminated 42 |
| Phase 1 | 6 | Terminated 6 |
| Phase 3 | 3 | Terminated 3 |
Follow Bronchitis: new trials by email Literature Review of Bronchitis trials Research Report on Bronchitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant Echocardiography Test, Ibrutinib - Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Terminated | Mayo Clinic | 2 | 2024-12-13 | 2026-05-22 |
| Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant Leflunomide tablet - Musculoskeletal Disease Other, GVHD, Chronic | Phase 2 | Terminated | Tata Memorial Centre | 1 | 2023-09-18 | 2025-09-10 |
| Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2023-03-10 | 2025-12-05 |
| Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant Ruxolitinib - Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO) | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 7 | 2021-11-12 | 2026-04-07 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib itacitinib - Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans) | Phase 2 | Terminated | Incyte Corporation | 18 | 2021-03-10 | 2026-06-26 |
| Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Itacitinib, Extracorporeal Photopheresis (ECP) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | University of Utah | 3 | 2021-01-29 | 2024-01-22 |
| A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) ION-827359, Placebo - Chronic Bronchitis, Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Ionis Pharmaceuticals, Inc. | 60 | 2020-12-22 | 2022-12-20 |
| A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) Itacitinib - Chronic Graft-versus-host-disease | Phase 2 | Terminated | SCRI Development Innovations, LLC | 15 | 2020-06-05 | 2024-11-06 |
| Anlotinib Treatment in Steroid Depenent/Refractory cGVHD Anlotinib - Chronic Graft-versus-host-disease | Phase 2 | Terminated | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 5 | 2020-04-10 | 2021-03-24 |
| A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4) Liposomal Cyclosporine A, Liposomal Placebo - Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic | Phase 2 | Terminated | Zambon SpA | 6 | 2020-02-11 | 2023-10-03 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Itacitinib - Bronchiolitis Obliterans Syndrome | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 23 | 2020-02-04 | 2025-10-20 |
| Ibrutinib and Rituxan for Chronic GVHD Rituximab, Ibrutinib - Graft Vs Host Disease | Phase 2 | Terminated | Northside Hospital, Inc. | 15 | 2019-12-16 | 2024-12-13 |
| Glasdegib for Chronic Graft-Versus-Host Disease Glasdegib - Chronic Graft Versus Host Disease, Fasciitis | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 15 | 2019-12-03 | 2024-10-29 |
| Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT Ibrutinib, Rituximab - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Terminated | Dartmouth-Hitchcock Medical Center | 2 | 2019-04-11 | 2023-11-28 |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Itacitinib, Placebo, Methylprednisolone - Chronic Graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | Incyte Corporation | 155 | 2019-01-17 | 2025-10-20 |
| Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Belumosudil (KD025) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | Kadmon, a Sanofi Company | 159 | 2018-10-11 | 2024-12-12 |
| Safety and Efficacy Study of SOM230 s.c. in Cluster Headache SOM230, Placebo - Cluster Headache - Episodic and Chronic | Phase 2 | Terminated | Novartis Pharmaceuticals | 28 | 2016-10-31 | 2021-01-05 |
| Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD Ponesimod - Chronic Graft Versus Host Disease | Phase 2 | Terminated | Actelion | 1 | 2016-09-29 | 2025-02-04 |
| Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) ENTO, Placebo - Chronic Graft Versus Host Disease | Phase 2 | Terminated | Gilead Sciences | 66 | 2016-05-27 | 2018-12-26 |
| The Effectiveness of Nebulized Hypertonic Saline Solution for Acute Bronchiolitis nebulized 3% hypertonic solution - Bronchiolitis | Phase 2 | Terminated | University Medical Centre Ljubljana | 100 | 2015-12-01 | 2019-08-05 |
Showing 20 of 42. Sign in to see all of them.
Bronchiolitis Obliterans Syndrome (32) · Bronchiolitis Obliterans (6) · Graft vs Host Disease (5) · Bronchiolitis (3) · Bronchitis, Chronic (2) · Leukemia (2) · Pulmonary Disease, Chronic Obstructive (2) · Asthma (1) · Breast Neoplasms (1) · Bronchiectasis (1) · Cluster Headache (1) · Cryptogenic Organizing Pneumonia (1) · Fasciitis (1) · Headache (1)
Bronchial Diseases (42) · Lung Diseases, Obstructive (42) · Respiratory Tract Diseases (42) · Lung Diseases (41) · Bronchiolitis (36) · Organizing Pneumonia (33) · Immune System Diseases (32) · Bronchiolitis Obliterans (30) · Graft vs Host Disease (27) · Infections (9) · Pathological Conditions, Signs and Symptoms (7) · Pathologic Processes (6) · Respiratory Tract Infections (6) · Chronic Disease (5)
itacitinib (5) · INCB039110 (4) · Rituximab (3) · ibrutinib (3) · Azithromycin (2) · Fluticasone (2) · Lenalidomide (2) · Prednisone (2) · Sirolimus (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Acupuncture Therapy (1) · Alefacept (1) · BMS-833923 (1) · Betamethasone (1) · Bortezomib (1)
Incyte Corporation (3) · M.D. Anderson Cancer Center (3) · Dana-Farber Cancer Institute (2) · Novartis Pharmaceuticals (2) · Actelion (1) · Alexion Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Boston Scientific Corporation (1) · Bristol-Myers Squibb (1) · Children's Hospital Medical Center, Cincinnati (1) · Dartmouth-Hitchcock Medical Center (1) · FLUIDDA nv (1) · Fred Hutchinson Cancer Center (1) · Gilead Sciences (1) · Ionis Pharmaceuticals, Inc. (1)
United States (26) · Canada (8) · Germany (8) · Belgium (6) · France (5) · Spain (5) · United Kingdom (5) · Italy (3) · Poland (3) · Austria (2) · China (2) · Finland (2) · Greece (2) · Israel (2) · South Korea (2)
Amin Alousi, MD (1) · Catherine Lee, MD (1) · Corey Cutler, MD (1) · Daniel R Couriel (1) · Daniele D'Ambrosio, MD, PhD (1) · Elizabeth F Krakow, MD,CM, FRCPC (1) · Francesco Blasi, MD (1) · Hyoung Jin Kang, MD, Ph.D (1) · Jamie Y Hur, D.O. (1) · Jayesh Mehta, MD (1) · John Kuruvilla (1)
PMID 21356110, PMID 23900970, PMID 24995515, PMID 25389139, PMID 26416925, PMID 34265047, PMID 35781099, PMID 37698881, PMID 38485149, PMID 40311075
2015 (2), 2019 (2), 2008 (1), 2018 (1), P30CA042014 (1)